Online citations, reference lists, and bibliographies.

Evaluation Of Whole Blood Serotonin And Plasma And Urine 5-Hydroxyindole Acetic Acid In Diagnosis Of Carcinoid Disease

R. Carling, T. Degg, K. Allen, N. Bax, J. Barth
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Background Carcinoid disease is an uncommon disorder resulting from tumours of the enterochromaffin cells. Current biochemical investigation usually involves the measurement of 5-hydroxyindole-3-acetic acid (5-HIAA) in 24-h urine collections. Because of the problems associated with urine collections (i.e. inconvenience, accuracy of collection and requirement for preservatives) two alternative markers, fasting plasma 5-HIAA and whole blood serotonin (5-hydroxytryptamine), have been studied. Methods and results Whole blood serotonin concentration and plasma and urine 5-HIAA concentrations were measured by high-performance liquid chromatography in 31 patients suspected of having carcinoid and 26 known carcinoid patients. Receiver operator characteristic curve analysis of the data showed no statistical difference between the three markers (P>0·01) with regard to their discriminating function. However, fasting plasma 5-HIAA assay showed greater stability than whole blood serotonin assay and is more convenient for the patient than a 24-h urine collection. At a cut-off value of 118 nmol/L plasma 5-HIAA assay showed a sensitivity of 89%, a specificity of 97% and a test efficiency of 93%. Whole blood serotonin assay was further limited by its saturation in platelets at 40 nmol/109 platelets which made it less suitable for monitoring the treatment of carcinoid disease. Conclusion Fasting plasma 5-HIAA concentration provides a more convenient screening test for carcinoid and overcomes the problems associated with 24-h urine collections, without any loss of diagnostic precision.
This paper references

This paper is referenced by
Primary carcinoid tumors at atypical sites: surgery is mandatory and size determines survival—an Egyptian study
Karim Moustafa (2019)
Tumeurs endocrines digestives : stratégie diagnostique
M. Mathonnet (2007)
Development of liquid chromatography mass spectrometric methods for quantification of metabolites from cellular level to clinical biomarkers
Niina Tohmola (2015)
Comparison of serum serotonin and serum 5-HIAA LC-MS/MS assays in the diagnosis of serotonin producing neuroendocrine neoplasms: A pilot study.
M. Lindström (2018)
Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method
E. Grouzmann (2018)
The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far
M. Ewang-Emukowhate (2019)
Measurement of plasma 5-hydroxyindole acetic acid by liquid chromatography tandem mass spectrometry--comparison with HPLC methodology.
A. G. Miller (2010)
A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy
A. Pucci (2015)
Gastrointestinal Carcinoids: The Evolution of Diagnostic Strategies
I. Modlin (2006)
Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors.
Christine S. Landry (2014)
Serotonin and GI clinical disorders
R. Spiller (2008)
Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors.
Martijn van Faassen (2019)
Hepatic arterial embolization in patients with neuroendocrine tumors
M. Del Prete (2014)
Neuroendocrine tumours of the small intestine.
J. Strosberg (2012)
Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?
R Basuroy (2015)
The spectrum of carcinoid tumours and carcinoid syndromes
C. Lips (2003)
Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review
S. Malla (2020)
Catecholamines and Serotonin
G. Eisenhofer (2012)
Workup of Gastroenteropancreatic Neuroendocrine Tumors.
J. Dillon (2020)
Circulating tumor markers in patients with neuroendocrine tumors - a clinical perspective
Thorvardur R Halfdanarson (2015)
The role of human and microbial metabolites of triptophane in severe diseases and critical ill (review)
M. Getsina (2020)
La caratterizzazione biologica dei NET: ruolo diagnostico e prognostico dei marcatori neuroendocrini
P. Ferolla (2006)
Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
T. Joy (2008)
Низкомолекулярные метаболиты являются промежуточными и конечными продуктами основных метаболических путей , отражают степень экспрессии генов , функциональную активность клеточных ферментов и другое , что позволяет рассматривать их в качестве вероятных участников патологических процессов и нередко к
M. Getsina (2020)
The Value of Biochemical Tests in the Diagnosis of Gastric Carcinoid Tumors: Case Report
Fatma Emel Kocak (2014)
Role of biomarker tests for diagnosis of neuroendocrine tumours
J. Hofland (2018)
Multimodal management of neuroendocrine liver metastases.
A. Frilling (2010)
Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
Liselotte B Christiansen (2019)
Symptom scores, serotonin and 5-hydroxyindole acetic acid levels in cancer patients with and without bowel obstruction
M. Bennett (2007)
Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples
K. Allen (2007)
Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms
Alexander Koenig (2017)
Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy
L. M. Veenendaal (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar